<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36859530</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>03</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-4889</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Mar</Month><Day>01</Day></PubDate></JournalIssue><Title>Cell death &amp; disease</Title><ISOAbbreviation>Cell Death Dis</ISOAbbreviation></Journal><ArticleTitle>Honokiol suppresses the aberrant interactions between renal resident macrophages and tubular epithelial cells in lupus nephritis through the NLRP3/IL-33/ST2 axis.</ArticleTitle><Pagination><StartPage>174</StartPage><MedlinePgn>174</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">174</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41419-023-05680-9</ELocationID><Abstract><AbstractText>Lupus nephritis (LN) is a type of immune-complex nephritis caused by systemic lupus erythematosus and is a major contributor to mortality and morbidity. Honokiol (HNK) has been found to have a therapeutic effect on LN, but its action mechanism remains unclear. In this study, we first demonstrated that HNK attenuates kidney injury in MRL/lpr mice. Results from RNA sequencing combined with ingenuity pathway analysis suggested that HNK plays an anti-LN role through inhibition of the NLRP3 inflammasome and IL33. GEO chip data, single-cell data, and clinical samples from LN patients demonstrated that the pyroptosis and IL-33/ST2 pathways are abnormally activated during the stage of LN. In vivo, similar to the results of the AAV-mediated NLRP3 shRNA MRL/lpr model, HNK downregulated serum and renal IL-33 levels, and suppressed NLRP3 inflammasome and the IL-33/ST2 axis in the kidney. In vitro, co-culturing NLRP3-overexpressing or IL-33 knocked-down rat renal macrophages with NRK-52E cells confirmed that NLRP3 activation in resident macrophages directly upregulates IL-33, which in turn mediates the IL-33/ST2/NF-&#x3ba;B pathway to promote the inflammatory response of renal tubular epithelial cells. Furthermore, a molecular docking model and surface plasmon resonance analysis were utilized to demonstrate a direct interaction between HNK and NLRP3. In conclusion, this study provides a novel anti-LN treatment strategy in which HNK plays a preventive and therapeutic role against LN by suppressing the abnormal crosstalk between renal resident macrophages and renal tubular epithelial cells by inhibiting the activation of the NLRP3/IL-33/ST2 axis.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Qing</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>The First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Mengyang</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jing</LastName><ForeName>Xin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Clinical Laboratory, Tongde Hospital of Zhejiang Province, Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qiu</LastName><ForeName>Jiang</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Medicine, Hangzhou Normal University, Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Shuo</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>School of Pharmaceutial Science, Zhejiang Chinese Medical University, Hang zhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Honghao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>School of Basic Medical Sciences, Zhejiang Chinese Medicine University, Hang zhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yin</LastName><ForeName>Lu</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Pathology, Affiliated Hangzhou First People's Hospital, School of Medicine, Zhejiang University, Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lou</LastName><ForeName>Jiang</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Lisha</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Medicine, Zhejiang Academy of Traditional Chinese Medicine, Hang zhou, China. 1669763749@qq.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>Yongsheng</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>The First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China. fyszjtcm@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qiu</LastName><ForeName>Ping</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-3497-907X</Identifier><AffiliationInfo><Affiliation>School of Pharmaceutial Science, Zhejiang Chinese Medical University, Hang zhou, China. dongguacha126@126.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Cell Death Dis</MedlineTA><NlmUniqueID>101524092</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000067596">Interleukin-33</NameOfSubstance></Chemical><Chemical><RegistryNumber>11513CCO0N</RegistryNumber><NameOfSubstance UI="C005499">honokiol</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000072179">Interleukin-1 Receptor-Like 1 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000071199">NLR Family, Pyrin Domain-Containing 3 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058847">Inflammasomes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C492716">Nlrp3 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C573346">Nlrp3 protein, rat</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000589812">ST2 protein, rat</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017472">Receptors, Interleukin-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019463" MajorTopicYN="N">Mice, Inbred MRL lpr</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000067596" MajorTopicYN="N">Interleukin-33</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072179" MajorTopicYN="N">Interleukin-1 Receptor-Like 1 Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071199" MajorTopicYN="N">NLR Family, Pyrin Domain-Containing 3 Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058847" MajorTopicYN="N">Inflammasomes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062105" MajorTopicYN="N">Molecular Docking Simulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007668" MajorTopicYN="N">Kidney</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004847" MajorTopicYN="N">Epithelial Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008264" MajorTopicYN="N">Macrophages</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017472" MajorTopicYN="N">Receptors, Interleukin-1</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>2</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>1</Day><Hour>23</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36859530</ArticleId><ArticleId IdType="pmc">PMC9977833</ArticleId><ArticleId IdType="doi">10.1038/s41419-023-05680-9</ArticleId><ArticleId IdType="pii">10.1038/s41419-023-05680-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>D&#xf6;rner T, Furie R. Novel paradigms in systemic lupus erythematosus. Lancet. 2019;393:2344&#x2013;58.. doi: 10.1016/S0140-6736(19)30546-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(19)30546-X</ArticleId><ArticleId IdType="pubmed">31180031</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanouriakis A, Tziolos N, Bertsias G, Boumpas DT. Update on the diagnosis and management of systemic lupus erythematosus. Ann Rheum Dis. 2021;80:14&#x2013;25. doi: 10.1136/annrheumdis-2020-218272.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-218272</ArticleId><ArticleId IdType="pubmed">33051219</ArticleId></ArticleIdList></Reference><Reference><Citation>Gergianaki I, Fanouriakis A, Repa A, Tzanakakis M, Adamichou C, Pompieri A, et al. Epidemiology and burden of systemic lupus erythematosus in a Southern European population: data from the community-based lupus registry of Crete, Greece. Ann Rheum Dis. 2017;76:1992&#x2013;2000. doi: 10.1136/annrheumdis-2017-211206.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2017-211206</ArticleId><ArticleId IdType="pubmed">28780511</ArticleId></ArticleIdList></Reference><Reference><Citation>Parikh SV, Almaani S, Brodsky S, Rovin BH. Update on lupus nephritis: core curriculum 2020. Am J Kidney Dis. 2020;76:265&#x2013;81.. doi: 10.1053/j.ajkd.2019.10.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.ajkd.2019.10.017</ArticleId><ArticleId IdType="pubmed">32220510</ArticleId></ArticleIdList></Reference><Reference><Citation>Anders HJ, Saxena R, Zhao MH, Parodis I, Salmon JE, Mohan C. Lupus nephritis. Nat Rev Dis Prim. 2020;6:7. doi: 10.1038/s41572-019-0141-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41572-019-0141-9</ArticleId><ArticleId IdType="pubmed">31974366</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma Y-C, Lin C-C, Li C-I, Chiang J-H, Li T-C, Lin J-G. Traditional Chinese medicine therapy improves the survival of systemic lupus erythematosus patients. Semin Arthritis Rheum. 2016;45:596&#x2013;603. doi: 10.1016/j.semarthrit.2015.09.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2015.09.006</ArticleId><ArticleId IdType="pubmed">26522135</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C, Zhang QW, Ye Y, Lin LG. Honokiol: a naturally occurring lignan with pleiotropic bioactivities. Chin J Nat Med. 2021;19:481&#x2013;90..</Citation><ArticleIdList><ArticleId IdType="pubmed">34247771</ArticleId></ArticleIdList></Reference><Reference><Citation>Rauf A, Olatunde A, Imran M, Alhumaydhi FA, Aljohani ASM, Khan SA, et al. Honokiol: a review of its pharmacological potential and therapeutic insights. Phytomedicine. 2021;90:153647. doi: 10.1016/j.phymed.2021.153647.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phymed.2021.153647</ArticleId><ArticleId IdType="pubmed">34362632</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang SR, Hsu WH, Wu CY, Shang HS, Liu FC, Chen A, et al. Accelerated, severe lupus nephritis benefits from treatment with honokiol by immunoregulation and differentially regulating NF-&#x3ba;B/NLRP3 inflammasome and sirtuin 1/autophagy axis. FASEB J. 2020;34:13284&#x2013;99.. doi: 10.1096/fj.202001326R.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.202001326R</ArticleId><ArticleId IdType="pubmed">32813287</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao RW, He SP, Lan JG, Zhu WZ. Honokiol ameliorates cisplatin-induced acute kidney injury via inhibition of mitochondrial fission. Br J Pharmacol. 2022;179:3886&#x2013;904.. doi: 10.1111/bph.15837.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.15837</ArticleId><ArticleId IdType="pubmed">35297042</ArticleId></ArticleIdList></Reference><Reference><Citation>Park EJ, Dusabimana T, Je J, Jeong K, Yun SP, Kim HJ, et al. Honokiol protects the kidney from renal ischemia and reperfusion injury by upregulating the glutathione biosynthetic enzymes. Biomedicines. 2020;8:9. doi: 10.3390/biomedicines8090352.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines8090352</ArticleId><ArticleId IdType="pmc">PMC7555803</ArticleId><ArticleId IdType="pubmed">32942603</ArticleId></ArticleIdList></Reference><Reference><Citation>Quan Y, Park W, Jin J, Kim W, Park SK, Kang KP. Sirtuin 3 activation by Honokiol decreases unilateral ureteral obstruction-induced renal inflammation and fibrosis via regulation of mitochondrial dynamics and the renal NF-&#x3ba;BTGF-&#x3b2;1/Smad signaling pathway. Int J Mol Sci 2020;21:402.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7014106</ArticleId><ArticleId IdType="pubmed">31936371</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z, Xiao G, Lyu M, Wang Y, He S, Du H, et al. Shuxuening injection facilitates neurofunctional recovery via down-regulation of G-CSF-mediated granulocyte adhesion and diapedesis pathway in a subacute stroke mouse model. Biomed Pharmacother. 2020;127:110213. doi: 10.1016/j.biopha.2020.110213.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2020.110213</ArticleId><ArticleId IdType="pubmed">32417690</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Wang S, Tan W, Lv B, Dai Y, Wang Y, et al. Dual-screening of anti-inflammatory and antioxidant active ingredients of shenxiang suhe pill and its potential multi-target therapy for coronary heart disease. Biomed Pharmacother. 2020;129:110283. doi: 10.1016/j.biopha.2020.110283.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2020.110283</ArticleId><ArticleId IdType="pubmed">32531677</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Zhou J, Liu J, Li S, Zhou S, Zhang C, et al. RNA-Seq analysis of the protection by Dendrobium nobile alkaloids against carbon tetrachloride hepatotoxicity in mice. Biomed Pharmacother. 2021;137:111307. doi: 10.1016/j.biopha.2021.111307.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2021.111307</ArticleId><ArticleId IdType="pubmed">33561648</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang T, Ye L, Han Z, Liu Y, Yang Y, Peng Z, et al. miR-19b-3p promotes colon cancer proliferation and oxaliplatin-based chemoresistance by targeting SMAD4: validation by bioinformatics and experimental analyses. J Exp Clin Cancer Res. 2017;36:131. doi: 10.1186/s13046-017-0602-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13046-017-0602-5</ArticleId><ArticleId IdType="pmc">PMC5610468</ArticleId><ArticleId IdType="pubmed">28938919</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng X, Yang T, Liu G, Liu H, Peng Y, He L. Piperine ameliorated lupus nephritis by targeting AMPK-mediated activation of NLRP3 inflammasome. Int Immunopharmacol. 2018;65:448&#x2013;57.. doi: 10.1016/j.intimp.2018.10.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2018.10.025</ArticleId><ArticleId IdType="pubmed">30388519</ArticleId></ArticleIdList></Reference><Reference><Citation>Obrisca B, Sorohan B, Tuta L, Ismail G. Advances in lupus nephritis pathogenesis: from bench to bedside. Int J Mol Sci. 2021;22:3766.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8038540</ArticleId><ArticleId IdType="pubmed">33916456</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon C, Amissah-Arthur MB, Gayed M, Brown S, Bruce IN, D&#x2019;Cruz D, et al. The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. Rheumatology. 2018;57:e1&#x2013;e45. doi: 10.1093/rheumatology/kex286.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kex286</ArticleId><ArticleId IdType="pubmed">29029350</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen PL, Eisenberg RA. Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Annu Rev Immunol. 1991;9:243&#x2013;69. doi: 10.1146/annurev.iy.09.040191.001331.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.iy.09.040191.001331</ArticleId><ArticleId IdType="pubmed">1910678</ArticleId></ArticleIdList></Reference><Reference><Citation>de Torre-Minguela C, Mesa Del Castillo P, Pelegr&#xed;n P. The NLRP3 and Pyrin inflammasomes: implications in the pathophysiology of autoinflammatory diseases. Front Immunol. 2017;8:43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5271383</ArticleId><ArticleId IdType="pubmed">28191008</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Hauenstein AV. The NLRP3 inflammasome: mechanism of action, role in disease and therapies. Mol Asp Med. 2020;76:100889. doi: 10.1016/j.mam.2020.100889.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mam.2020.100889</ArticleId><ArticleId IdType="pubmed">32859386</ArticleId></ArticleIdList></Reference><Reference><Citation>Ummarino D. Lupus nephritis: NLRP3 inflammasome ignites podocyte dysfunction. Nat Rev Rheumatol. 2017;13:451. doi: 10.1038/nrrheum.2017.97.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2017.97</ArticleId><ArticleId IdType="pubmed">28592896</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu D, Ai L, Sun Y, Yang B, Chen S, Wang Q, et al. Role of NLRP3 Inflammasome in lupus nephritis and therapeutic targeting by phytochemicals. Front Pharmacol. 2021;12:621300. doi: 10.3389/fphar.2021.621300.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2021.621300</ArticleId><ArticleId IdType="pmc">PMC8417800</ArticleId><ArticleId IdType="pubmed">34489689</ArticleId></ArticleIdList></Reference><Reference><Citation>Furini F, Giuliani AL, Parlati ME, Govoni M, Di Virgilio F, Bortoluzzi A. P2X7 receptor expression in patients with serositis related to systemic lupus erythematosus. Front Pharmacol. 2019;10:435. doi: 10.3389/fphar.2019.00435.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2019.00435</ArticleId><ArticleId IdType="pmc">PMC6501575</ArticleId><ArticleId IdType="pubmed">31110478</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang CA, Huang ST, Chiang BL. Sex-dependent differential activation of NLRP3 and AIM2 inflammasomes in SLE macrophages. Rheumatology. 2015;54:324&#x2013;31. doi: 10.1093/rheumatology/keu318.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keu318</ArticleId><ArticleId IdType="pubmed">25161312</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo C, Fu R, Zhou M, Wang S, Huang Y, Hu H, et al. Pathogenesis of lupus nephritis: RIP3 dependent necroptosis and NLRP3 inflammasome activation. J Autoimmun. 2019;103:102286. doi: 10.1016/j.jaut.2019.05.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2019.05.014</ArticleId><ArticleId IdType="pmc">PMC6708470</ArticleId><ArticleId IdType="pubmed">31133359</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliveira CB, Lima CAD, Vajgel G, Sandrin-Garcia P. The role of NLRP3 inflammasome in lupus nephritis. Int J Mol Sci. 2021;22:12476.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8625721</ArticleId><ArticleId IdType="pubmed">34830358</ArticleId></ArticleIdList></Reference><Reference><Citation>Liew FY, Girard JP, Turnquist HR. Interleukin-33 in health and disease. Nat Rev Immunol. 2016;16:676&#x2013;89.. doi: 10.1038/nri.2016.95.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri.2016.95</ArticleId><ArticleId IdType="pubmed">27640624</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan XY, Jing HY, Ma YR. Interleukin-33/ suppression of tumorigenicity 2 in renal fibrosis: emerging roles in prognosis and treatment. Front Physiol. 2021;12:792897. doi: 10.3389/fphys.2021.792897.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphys.2021.792897</ArticleId><ArticleId IdType="pmc">PMC8761767</ArticleId><ArticleId IdType="pubmed">35046838</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005;23:479&#x2013;90. doi: 10.1016/j.immuni.2005.09.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2005.09.015</ArticleId><ArticleId IdType="pubmed">16286016</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen WY, Li LC, Yang JL. Emerging roles of IL-33/ST2 axis in renal diseases. Int J Mol Sci. 2017;18:4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5412367</ArticleId><ArticleId IdType="pubmed">28387719</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreau A, Nicaise C, Awada A, Soyfoo MS. Soluble ST2 is increased in systemic lupus erythematous and is a potential marker of lupus nephritis. Clin Exp Rheumatol. 2021;40:897&#x2013;903.</Citation><ArticleIdList><ArticleId IdType="pubmed">34128798</ArticleId></ArticleIdList></Reference><Reference><Citation>Munro DAD, Hughes J. The origins and functions of tissue-resident macrophages in kidney development. Front Physiol. 2017;8:837. doi: 10.3389/fphys.2017.00837.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphys.2017.00837</ArticleId><ArticleId IdType="pmc">PMC5660965</ArticleId><ArticleId IdType="pubmed">29118719</ArticleId></ArticleIdList></Reference><Reference><Citation>Culemann S, Gr&#xfc;neboom A, Nicol&#xe1;s-&#xc1;vila J, Weidner D, L&#xe4;mmle KF, Rothe T, et al. Locally renewing resident synovial macrophages provide a protective barrier for the joint. Nature. 2019;572:670&#x2013;5. doi: 10.1038/s41586-019-1471-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-1471-1</ArticleId><ArticleId IdType="pmc">PMC6805223</ArticleId><ArticleId IdType="pubmed">31391580</ArticleId></ArticleIdList></Reference><Reference><Citation>Dick SA, Macklin JA, Nejat S, Momen A, Clemente-Casares X, Althagafi MG, et al. Self-renewing resident cardiac macrophages limit adverse remodeling following myocardial infarction. Nat Immunol. 2019;20:29&#x2013;39. doi: 10.1038/s41590-018-0272-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-018-0272-2</ArticleId><ArticleId IdType="pmc">PMC6565365</ArticleId><ArticleId IdType="pubmed">30538339</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang S, Nakanishi Y, Kioi Y, Okuzaki D, Kimura T, Takamatsu H, et al. Semaphorin 6D reverse signaling controls macrophage lipid metabolism and anti-inflammatory polarization. Nat Immunol. 2018;19:561&#x2013;70.. doi: 10.1038/s41590-018-0108-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-018-0108-0</ArticleId><ArticleId IdType="pubmed">29777213</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochheiser IV, Pilsl M, Hagelueken G, Moecking J, Marleaux M, Brinkschulte R, et al. Structure of the NLRP3 decamer bound to the cytokine release inhibitor CRID3. Nature. 2022;604:184&#x2013;9. doi: 10.1038/s41586-022-04467-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04467-w</ArticleId><ArticleId IdType="pubmed">35114687</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark AM, Labute P. 2D depiction of protein-ligand complexes. J Chem Inf Model. 2007;47:1933&#x2013;44. doi: 10.1021/ci7001473.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ci7001473</ArticleId><ArticleId IdType="pubmed">17715911</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>